Novartis

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitab...

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole...

Beta thalassemia, globally affects almost 288,000 people, with an incidence of 60,000 cases every year. A rare monogenic genetic disease, beta-thalassemia is caused by more than 200 mutations of the beta-globin gene (HBB). The Beta-thalassemia pharmacological treatment mainly comprises of regular blood-transfus...

The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy in clinical trials for the treatment of Primary and Secondary hypogonadism in males. The drug contains containing Testosterone Undecanoate (TU) which help...

Rapt Therapeutics files for IPO at $75M Rapt Therapeutics, based in the US, filed to raise to $75 million in its IPO. This had come after five months when the company had retitled itself, which was earlier known as Flx Bio and after three months, it had filed its initial S-1 form with the hope to gain $86 millio...

Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, the drug developed by Boehringer Ingelheim Pharmaceuticals, has shown efficacy in slowing down the rate of decline in pul...

Vertex Pharmaceuticals recently has announced the acquisition of Semma Therapeutics for USD 950 million in cash. Vertex Pharmaceuticals, aimed at creating therapies for life-threatening diseases, like cystic fibrosis, has signed a definitive agreement with Semma therapeutics, working to bring in the Healthcare ...

Helsinn Group grants exclusive licensing rights to Blanver and Varifarma for its leading drug Pracinostat in South America. Helsinn is a Swiss biopharmaceutical company committed to producing the best solutions aimed at improving the quality of life for people with cancer. Under the terms of the agreements, ...

EU recommends the use of Imbruvica for two new indications The Janssen Pharmaceutical has received the approval for its drug Imbruvica (ibrutinib) from the European Commission (EC). Ibrutinib is a first-in-class targeted therapy, which inhibits the function of Bruton's tyrosine kinase (BTK). Jointly developed an...

Bluebird declares the price of its gene therapy- Zynteglo Bluebird Bio has set the price of its gene therapy Zynteglo at USD 1.8 million. Zynteglo, so far, has only been approved for treating rare blood disorders in the Europe Union. The full price of Zynteglo can be dispersed out for five years, at approx...